From Sample to Insight: Technologies Driving the Future of Precision Oncology Assays
supports precision therapy selection, clinical trial enrollment, and monitoring of treatment response or minimal residual disease (MRD). • WGS plays a critical role in exploratory analysis, especially in complex, treatment-resistant, or rare cancer cases where other methods fail to reveal actionable findings. Its unbiased, whole-genome coverage helps uncover novel driver mutations, structural rearrangements and noncoding alter-
ations that may influence tumor behavior or drug resistance. While other traditional (digital PCR) and emerging technologies continue to shape research and discovery in academic settings, these three remain central to current diagnostic offerings. Together, these platforms form a complementary diagnostic continuum—where qPCR provides fast answers for established biomarkers, tNGS offers
Table 3. Overview of CLIA-approved EGS assays supporting precision oncology.
Highest
Table 4. Summary of key differences: qPCR vs tNGS vs. WGS in precision oncology diagnostics.
GENengnews.com | 17
Powered by FlippingBook